United StatesÚltimas notícias

Gilead Sciences (NASDAQ:GILD) and Merck (NYSE:MRK) said their once-weekly HIV pill maintained suppression through Week 48 in two Phase 3 trials.

On this episode of Stock Movers: - Cracker Barrel (CBRL) shares are higher after the restaurant chain said it now expects to exceed its adjusted Ebitda outlook, and achieve or exceed the high end of its revenue range for fiscal 2026 following two completed strategic transactions. - Danaher (DHR) shares are tumbling after the life sciences firm gave core revenue growth guidance for the third quarter that fell short of the average analyst estimate. - Equifax (EFX) shares are lower after the company lowered the top end of its adjusted earnings per share forecast for the full year and lifted the bottom end of the guide. The midpoints of the new guidance for the third quarter and full fiscal year are below analyst estimates.

Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls misleading ads about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo's Wegovy to Lilly's Zepbound. John Kuckelman, Novo Nordisk Group general counsel and senior vice president, speaks on "Bloomberg Open Interest." Lilly says in a statement to Bloomberg that it's ads are "truthful" and "transparent" and the company will defend "vigorously" against the Novo lawsuit.  (Corrects spelling of Novo Nordisk)

Charles Schwab (NYSE:SCHW) reported record Q2 net revenue of $7.07 billion, up 21%, while net income increased 32% to $2.8 billion.

Microsoft (NASDAQ:MSFT) agreed to spend billions on Mistral AI’s European infrastructure while expanding the French startup’s distribution through Azure.

Bearish bets across US stocks are surging to a record in the face of market gains, reflecting anxiety about the staying power of a rally that has seen the S&P 500 jump 18% from late March. Short interest in S&P 500 Index stocks is sitting steps away from 3.79% of free float, an all-time high in data tracked by S3 Partners LLC going back to 2010. For the Russell 3000 companies, the figure has recently climbed to 6.3%, a record. While betting against stocks has generally been a losing proposition this year, short sellers are sticking to their guns as worries about the payoff from artificial intelligence investments keep rattling the markets. Concerns about AI-related spending and competition from China sent the S&P 500 down 1.6% last week. Tom Thornton, President at Hedge Fund Telemetry, joins Bloomberg Businessweek Daily to discuss market sentiment and his call in late May about pressure and leverage in Korean equities.

Tempus AI (NASDAQ:TEM) agreed to acquire Personalis (NASDAQ:PSNL) for $1.5 billion, adding cancer-monitoring technology to its oncology platform.

Novo Nordisk (NYSE:NVO) sued Eli Lilly (NYSE:LLY) in New Jersey, challenging GLP-1 advertisements served more than 700 million times.

Bluejay Diagnostics (NASDAQ:BJDX) completed enrollment of 750 patients in its SYMON-II study evaluating 28-day sepsis mortality risk.

Forestar Group (NYSE:FOR) reported fiscal Q3 revenue of $407.0 million, up 4%, as residential lot sales increased 1% to 3,659.

Southern First Bancshares (NASDAQ:SFST) reported Q2 2026 net income of $11.2 million as total revenue increased 25% to $35.9 million.

Hasbro (NASDAQ:HAS) reported Q2 revenue of $1.14 billion, up 16%, and raised its 2026 revenue-growth outlook to 5%–7%.